About the Authors

Andrea Malandrino

Contributed equally to this work with: Andrea Malandrino, Michael Mak

Roles Conceptualization, Formal analysis, Funding acquisition, Investigation, Methodology, Writing – original draft, Writing – review & editing

andrea.malandrino@embl.es (AM); rdkamm@mit.edu (RDK); Michael.Mak@Yale.edu (MM)

Current address: European Molecular Biology Laboratory, Barcelona, Spain

Affiliations Department of Mechanical Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts, United States of America, Institute for Bioengineering of Catalonia, Barcelona, Spain

Xavier Trepat

Roles Resources, Supervision

Affiliations Institute for Bioengineering of Catalonia, Barcelona, Spain, Unitat de Biofísica i Bioenginyeria, Facultat de Medicina, Universitat de Barcelona, Barcelona, Spain, Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain, Centro de Investigación Biomédica en Red en Bioingeniería, Biomateriales y Nanomedicina, Madrid, Spain

Roger D. Kamm

Roles Conceptualization, Formal analysis, Resources, Supervision, Writing – original draft, Writing – review & editing

andrea.malandrino@embl.es (AM); rdkamm@mit.edu (RDK); Michael.Mak@Yale.edu (MM)

Affiliations Department of Mechanical Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts, United States of America, Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts, United States of America

Michael Mak

Contributed equally to this work with: Andrea Malandrino, Michael Mak

Roles Conceptualization, Formal analysis, Funding acquisition, Investigation, Methodology, Resources, Supervision, Writing – original draft, Writing – review & editing

andrea.malandrino@embl.es (AM); rdkamm@mit.edu (RDK); Michael.Mak@Yale.edu (MM)

Affiliation Yale University, Biomedical Engineering Department, New Haven, Connecticut, United States of America

Competing Interests

I have read the journal's policy and the authors of this manuscript have the following competing interests: R.K. is a cofounder of and has a substantial financial interest in AIM Biotech, a company that has commercialized microfluidic assays with designs similar to the one described in the present protocol. All the reported studies, however, were performed with devices designed and fabricated at the Kamm laboratory at MIT.